Last reviewed · How we verify
ASP8477
ASP8477 is a small molecule that targets the CDK9 protein.
ASP8477 is a small molecule that targets the CDK9 protein. Used for Relapsed or refractory non-Hodgkin lymphoma.
At a glance
| Generic name | ASP8477 |
|---|---|
| Sponsor | Astellas Pharma Europe B.V. |
| Drug class | CDK inhibitor |
| Target | CDK9 |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 2 |
Mechanism of action
By inhibiting CDK9, ASP8477 aims to reduce the expression of oncogenic genes and induce apoptosis in cancer cells.
Approved indications
- Relapsed or refractory non-Hodgkin lymphoma
Common side effects
- Fatigue
- Nausea
- Diarrhea
Key clinical trials
- A Study Into Pain Relief Given by ASP8477 for Peripheral Neuropathic Pain (Either Post-herpetic Neuralgia or Painful Diabetic Peripheral Neuropathy) and Its Safety (PHASE2)
- A Study to Assess the Effects of Single Ascending Doses (SAD) of ASP8477, the Effect That Food Has on the Drug, and the Interaction Between ASP8477 and Omeprazole in Healthy Postmenopausal Females and Healthy Young Vasectomized Males (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- ASP8477 CI brief — competitive landscape report
- ASP8477 updates RSS · CI watch RSS
- Astellas Pharma Europe B.V. portfolio CI